Apollo And ReShape Swap Bariatric Devices

Apollo Endosurgery sold its surgical product line, including the Lap-Band adjustable gastric banding system and other accessories for laparoscopic bariatric surgery, to ReShape Lifesciences for $17m plus other considerations, including the ReShape endoscopic balloon, the companies announced Dec. 18. The deal will allow Apollo to focus on endo-bariatric procedures while it gives ReShape an instant revenue stream and another product to sell to surgeons, its core customers.

3d render illustration of human digestive system - front view

ReShape Lifesciences Inc. has acquired the Lap-Band adjustable gastric band surgery system from Apollo Endosurgery Inc. in exchange for $17m and the ReShape Balloon intra-gastric bariatric product line, the companies announced Dec. 18.

In addition to the product-swap, ReShape has agreed to pay Apollo $17m, including $10m paid at closing and $7m to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By 

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.